Cytosorbents Corporation (CTSO) Stock Analysis
A live, multi-source view of Cytosorbents Corporation (CTSO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies.
Sector: Healthcare · Industry: Medical Devices · United States · 129 employees · cytosorbents.com
CTSO earnings date
No earnings report for Cytosorbents Corporation (CTSO) is on the Finnhub calendar through Friday, October 2, 2026.
Source: Finnhub earnings calendar, filtered to RapidTradeView’s universe; times are Eastern. Earnings today · This week
Key statistics · as of 2026-09-11
As of 2026-09-11, Cytosorbents Corporation (CTSO) had a market capitalization of $20.1M and a beta of 1.34; the shares traded in a 52-week range of $6.00 – $20.40 (-66.3% over the year).
- Market cap
- $20.1M
- Enterprise value
- $45.0M
- EPS (trailing)
- $-5.84
- EPS (forward)
- $0.00
- Payout ratio
- 0.0%
- 52-week range
- $6.00 – $20.40
- 52-week change
- -66.3%
- Beta
- 1.34
- Average volume
- 12,982
- Shares outstanding
- 3.2M
- Short % of float
- 3.98%
- Profit margin
- -48.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-17
In RapidTradeView’s 2026-09-17 scan of the US universe, Cytosorbents Corporation (CTSO) last closed at $5.73 (the last completed close before that scan).
Technicals at the scan: RSI 86 (overbought territory), price +174.2% versus its 20-day average, 20-day versus 50-day average spread +97.2%, MACD histogram 0.59.
Sentiment inputs: StockTwits 60% bullish.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of CTSO; corporate insiders filed 7 buys and 0 sells (3 distinct filers, latest disclosure 2026-09-16). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Alan D. Sobel (3B/0S), Phillip P. Chan (2B/0S), Vincent Capponi (2B/0S). Who is trading what
RapidTradeView pick record
CTSO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Cytosorbents Corporation (CTSO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CTSO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.